Comment: Local guidance is available from the Forth Valley Asthma Online Resource and COPD Guidance

Also see British Guideline on the Management of Asthma and <u>NICE guideline [NG115] Chronic obstructive pulmonary disease in over 16s: diagnosis and management</u>

In new patients, consideration should be given to prescribing formulary choice dry powder inhaler (DPI) devices rather than metered dose inhalers (MDI) in order to reduce the carbon footprint.

Inhaler devices which are carbon neutral or with a low carbon footprint are marked as for further information on how to reduce the carbon footprint on inhaler prescribing refer to https://www.greenerpractice.co.uk/greener-practice-guide-to-inhaler-prescribing

1 A	irways Disease, Obstructive	Primary Care	Acute/ Specialist Services
Antii	muscarinics (inhaled)		
Long	-acting Antimuscarinic Monotherapy (LAMA)		
	Incruse Ellipta [®] (Umeclidinium) (DPI) (1 st line) (licensed for use in those aged 18 years old and upwards)	✓	✓
	Spiriva Respimat [®] (Tiotropium) (Soft mist inhaler[SMI]) (2 nd line) (licensed for use in those aged 6 years old and upwards in asthma)	✓	✓
Short	t-acting Antimuscarinic Monotherapy (SAMA)		
	Ipratropium nebules	✓	✓
Coml	bination Inhalers	•	
Long	-acting Antimuscarinic and Long-acting Beta2-adrenoceptor agonist	inhaler (LAM	A + LABA)
	Anoro Ellipta [®] (Umeclidinium + vilanterol) (DPI) (1 st line) (licensed for use in those aged 18 years old and upwards)	✓	✓
	Spiolto Respimat® (Tiotropium + olodaterol) (SMI) (2 nd line) (licensed for use in those aged 18 years old and upwards)	✓	✓
	Bevespi Aerosphere [®] (Glycopyrronium + formoterol) (MDI) (licensed for use in those aged 18 years old and upwards)	✓	✓
Short	t-acting Beta ₂ -adrenoceptor agonist + Short-acting Antimuscarinic (S	SABA + SAMA	<u>, </u>
	Salbutamol + ipratropium nebules	✓	✓
Beta ₂	-adrenoceptor agonists		
Long	-acting		
	No formulary choice as monotherapy		
Short	t-acting (SABA)		
	Salbutamol (Easyhaler [®] salbutamol) (DPI) (licensed for use from age 4 years and upwards)	✓	✓
	Salbutamol (MDI)	✓	✓
	Salbutamol nebules	✓	✓

Comment: Different brands of salbutamol MDI have different carbon footprints e.g. Salamol[®] inhaler has a lower carbon footprint than Ventolin Evohaler[®]. Consideration should be given to prescribing salbutamol MDI's by brand name (this will ensure a lower carbon footprint inhaler is dispensed by the Pharmacy), in new patients/when patients are reviewed and they consent to being prescribed a lower carbon footprint MDI.

Patients using more than 6 SABA inhalers per annum should be reviewed to ensure appropriate management of the

(ICS + LABA + LAMA)

patien	t's asthma.		
Corti	costeroids (inhaled)		
	nent: See <u>HIS Steroid Emergency Card</u> for further info. regarding patients who are all crisis and should be provided with a steroid emergency card.	considered at h	nigh risk of
Corti	costeroid Monotherapy		
	Easyhaler® Beclomethasone (1st line DPI)	✓	✓
-	(licensed for use in those aged 18 years and upwards)		
	Easyhaler® Budesonide (2 nd line DPI)	✓	✓
	(licensed for use in those aged 6 years and upwards)		
	Soprobec [®] (1 st line MDI) (Beclometasone Dipropionate)	✓	✓
	(200mcg, 250mcg strengths not licensed for use in children less than 12 years old)		
Comb	pination Inhalers		
nhal	ed Corticosteroid + Long-acting Beta ₂ -adrenoceptor agonist (ICS + L	ABA)	
Asthr	ma		
	Fostair NEXThaler® 100/6, 200/6	✓	✓
	(Beclometasone extra-fine + formoterol) (1 st line DPI)		
	(licensed for use in those aged 18 years old and upwards)		
	Relvar Ellipta® 92/22,184/22 (Fluticasone furoate + vilanterol) (1st line DPI) (licensed for use in those aged 12 years old and upwards in asthma)	✓	✓
	Fobumix Easyhaler® 80/4.5,160/4.5,320/9 (Budesonide + formoterol) (2 nd line DPI) (licensed for use in those aged 18 years old and upwards)	✓	✓
	nent: Fobumix Easyhaler [®] is licensed for use in adults only. In younger patients Syscribed in patients requiring budesonide + formoterol.	mbicort Turboh	aler [®] should
	Luforbec [®] 100/6, 200/6 (Beclometasone extra-fine + formoterol) (1 st line MDI) (licensed for use in those aged 18 years old and upwards)	✓	✓
	Flutiform® (Fluticasone propionate + formoterol) (2 nd line (MDI)	✓	✓
	(50/5mcg inhaler licensed for use in those aged 5 years old and upwards, 125/5mcg inhaler licensed from 12 years old, 250/10mcg inhaler only licensed in adults)		
Comn	nent: Flutiform [®] has a high carbon footprint and should only be considered if altern	ative options ar	e unsuitable
	nent: Luforbec [®] MDI shelf life is 3 months after dispensing – prescribe appropriate essary wastage	quantities to av	oid/
COPI			
	Fostair NEXThaler® 100/6 (Beclometasone extra-fine + formoterol) (1st line DPI) (licensed for use in those aged 18 years old and upwards)	✓	✓
	Relvar Ellipta® 92/22 (Fluticasone furoate + vilanterol) (1st line DPI)	✓	✓
•	(licensed for use in those aged 18 years old and upwards)		
	Fobumix Easyhaler® 160/4.5,320/9 (Budesonide + formoterol inhaler) (2 nd line DPI) (licensed for use in those aged 18 years old and upwards)	✓	✓
	Luforbec [®] 100/6 (Beclometasone extra-fine + formoterol) (1 st line MDI) (licensed for use in those aged 18 years old and upwards)	✓	√

Key ✓ **Initiate and continue ♦Continue where appropriate.**

Asthn	na			
	Trimbow [®] 87/5/9mcg, 172/5/9mcg (Beclometasone + formoterol + glycopyrronium) (MDI)	✓	✓	
	(licensed for use in those aged 18 years old and upwards)			
COPE				
	Trelegy Ellipta® (Fluticasone furoate + vilanterol + umeclidinium) (DPI) (licensed for use in those aged 18 years old and upwards)	✓	✓	
	Trimbow® NEXThaler® 88/5/9mcg(Beclometasone + formoterol + glycopyrronium) (DPI)	✓	√	
	licensed for use in those aged 18 years old and upwards)			
	Trimbow [®] 87/5/9mcg(Beclometasone + formoterol + glycopyrronium) (MDI) (licensed for use in those aged 18 years old and upwards)	✓	√	
	Trixeo Aerosphere® (Budesonide + formoterol + glycopyrronium) (MDI) (licensed for use in those aged 18 years old and upwards)	*	>	
Immunosuppresants - Monoclonal Antibodies				
	Mepolizumab (Nucala®) (1st line)		✓	
	Benralizumab (Fasenra®) (2 nd line)		✓	
	Omalizumab (Xolair [®])		✓	
Comment: Monoclonal antibodies are restricted to use by clinicians responsible for adults with severe asthma. To be prescribed in line with SMC restrictions.				
Leuko	triene Receptor Antagonists			
	Montelukast	✓	✓	
Comment: For patients with swallowing problems it is more cost-effective to use chewable tablets rather than granules				
Xanthines				
	Aminophylline Injection		✓	
	Theophylline tablets (Uniphyllin Continus®)	✓	✓	
Peak flow meters				
	Easy Peak Flow Meter (Low range, standard range)	✓	✓	
Inhale	rmSpacers			
	Easychamber [®] Spacer +/-mask	✓	✓	
Comment : Spacer + MDI is recommended in preference to dry powder or breath actuated inhalers in younger children Spacers should be replaced at least every year, especially if the spacer is used on a daily basis. May need to be replaced sooner in some individuals.				

Antihistamines – Non-sedating		
Cetirizine (1 st line)	✓	✓
Loratadine (1 st line)	✓	✓
Fexofenadine (2 nd line)	✓	✓
Antihistamines – Sedating		
Chlorphenamine	✓	✓
Promethazine	✓	✓
2.1 Angiodema		
Treatments for angiodema are available via tertiary centres		
3. Conditions Affecting Sputum Viscosity	Primary Care	Acute/ Specialist Services
Mucolytics		
Acetylcysteine effervescent tablets (NACSYS®) (1st line in patients aged 18 years and above)	*	*
Carbocisteine (1 st line in patients aged 2 - 18 years)	✓	✓
3.1 Cystic Fibrosis		
Treatments for cystic fibrosis are available via a tertiary centre in NHS Lothian		
4. Cough and Congestion		
No formulary choices		
5. Idiopathic Pulmonary Fibrosis		
Pirfenidone		✓
Nintedanib (Ofev®)		✓
Comment: Pirfenidone, nintedanib to be prescribed in line with SMC restrictions		

6. Re apno	espiratory depression, respiratory distress syndrome and bea	Primary Care	Acute/ Specialist Services
Respiratory stimulants			
	Doxapram hydrochloride		√